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ABSTRACT
Objective: To review the evidence for existing
prognostic models in acute pulmonary embolism (PE)
and determine how valid and useful they are for
predicting patient outcomes.
Design: Systematic review and meta-analysis.
Data sources: OVID MEDLINE and EMBASE, and The
Cochrane Library from inception to July 2014, and
sources of grey literature.
Eligibility criteria: Studies aiming at constructing,
validating, updating or studying the impact of prognostic
models to predict all-cause death, PE-related death or
venous thromboembolic events up to a 3-month
follow-up in patients with an acute symptomatic PE.
Data extraction: Study characteristics and study
quality using prognostic criteria. Studies were selected
and data extracted by 2 reviewers.
Data analysis: Summary estimates (95% CI) for
proportion of risk groups and event rates within risk
groups, and accuracy.
Results: We included 71 studies (44 298 patients).
Among them, 17 were model construction studies
specific to PE prognosis. The most validated models
were the PE Severity Index (PESI) and its simplified
version (sPESI). The overall 30-day mortality rate was
2.3% (1.7% to 2.9%) in the low-risk group and 11.4%
(9.9% to 13.1%) in the high-risk group for PESI (9
studies), and 1.5% (0.9% to 2.5%) in the low-risk
group and 10.7% (8.8% to12.9%) in the high-risk
group for sPESI (11 studies). PESI has proved
clinically useful in an impact study. Shifting the cut-off
or using novel and updated models specifically
developed for normotensive PE improves the ability for
identifying patients at lower risk for early death or
adverse outcome (0.5–1%) and those at higher risk
(up to 20–29% of event rate).
Conclusions: We provide evidence-based information
about the validity and utility of the existing prognostic
models in acute PE that may be helpful for identifying
patients at low risk. Novel models seem attractive for
the high-risk normotensive PE but need to be
externally validated then be assessed in impact studies.
INTRODUCTION
Venous thromboembolism (VTE), including
pulmonary embolism (PE) and deep vein
thrombosis (DVT), is a common and poten-
tially fatal disorder, despite improvements
in its management. The main short-term
complications of PE are all-cause death,
PE-related death, VTE events and bleeding.
In acute PE, there is a real clinical ques-
tioning and interest on how to choose the
appropriate management for a speciﬁc
patient.1–4 Usual care in the early phase is to
treat patients in hospital and to use
Strengths and limitations of this study
▪ Comprehensive systematic review and
meta-analysis of prognostic models in acute pul-
monary embolism (PE) that was not restricted to
only clinical prediction rules and derivation or
validation studies, but was expanded to all avail-
able prediction/predictive models including
update and impact studies to inform clinical
decisions, with broad search strategy and prede-
fined selection criteria, and no data or language
restriction.
▪ Study quality assessed by using prognostic cri-
teria more appropriate than diagnostic tools for
prognostic studies and by using a domain
approach, and full details on study character-
istics provided.
▪ Quantitative analyses performed for ‘both stable
and unstable PE’ and for ‘stable PE’, for each
outcome/time point separately, and for every
available risk cut-off for a model to assess how a
model performs along the risk scale, and results
provided in terms of summary estimates of pro-
portion of risk groups and event rates within risk
groups in ‘absolute risk’ more meaningful for
clinicians and more appropriate for the study of
prognosis, and summary estimates of sensitivity
and specificity (accuracy).
▪ Not included in the systematic review because
they deserve specific reviews, studies performed
in selective populations such as in asymptomatic
PE, unstable PE, patients with cancer, elderly
patients, or studies restricted to only a single
risk group (low-risk or high-risk group) with the
exception of impact studies.
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anticoagulants in normotensive patients or rescue
thrombolysis in patients with hypotension or cardiogenic
shock. In normotensive patients, other options are avail-
able that might depend on the estimated risk for
adverse outcomes for the individual patient and include
home treatment for patients at low risk, or closer moni-
toring and escalating therapy for patients at high risk.
Prognostic tools seek to classify patients by their risk of
adverse outcomes to help select the appropriate man-
agement for an individual patient. The European
Society of Cardiology 2008 guidelines1 suggest using the
haemodynamic status based on systolic blood pressure
(SBP) and signs of right ventricular dysfunction (RVD)
and ischaemia. The American Heart Association (AHA)
Scientiﬁc Statement2 considers that patients with low-risk
stable PE with no prognostic markers of RVD/ischaemia
‘may still have signiﬁcant rates of morbidity and mortal-
ity that are functions of older age and comorbidities’.
Systematic reviews of individual prognostic variables5–9
have shown inconsistent results across studies, leading to
the development of prognostic models. The large
number of studies of existing prognostic models and the
differences between them suggest the need for a system-
atic review that could assess study quality, synthesise ﬁnd-
ings across studies, assess the validity of the original
models and provide the best estimate from the model.
Determining which prognostic models work, and which
work best, may impact on clinical decisions and on
research.
This systematic review assesses the characteristics and
quality of studies of prognostic models in patients with
acute PE. It investigates the performance and utility of
the prognostic models, along their different phases of
development in construction, validation, update and
impact studies.
METHODS
Selection criteria
Criteria for considering studies for this review were
derived from previous reviews of prognostic models.10–13
To be eligible, studies had to have developed a prognos-
tic model to predict the outcome of patients with an
acute symptomatic PE, with the speciﬁc aim of construct-
ing a new prognostic model or validating, updating or
studying the impact of an existing one. The models
needed to contain a combination of at least two prog-
nostic variables to predict patient outcome, incorporated
from across the following characteristics: demographic/
clinical, biological and imaging related. Patient out-
comes were death, PE-related death or VTE (DVT or
PE) recurrence. Only hospital-based studies were consid-
ered for inclusion.
Prognostic studies validating individual prognostic
indicators, population-based studies, studies performed
in selective populations (asymptomatic PE, unstable PE,
patients with cancer, elderly patients, speciﬁc risk group
except when assessed in impact studies) or considering
only surrogate outcomes were not included. As they
include prognostic and practical variables for hospitalisa-
tion, checklists of exclusion criteria from early discharge
or home treatment were not considered strictly prognos-
tic. Thus, studies on safety of early discharge or home
treatment based on these criteria were not included
unless their objective was clearly to derive and validate
the checklist or to compare it with existing prognostic
models. Unpublished articles or those published only as
conference abstracts, discussion articles on prognostic
models or indicators or patient management were not
included. If a study was published more than once, the
ﬁrst published article or the article combining cumula-
tive results from different studies was included.
Search methods and search strategy
Studies were sought through electronic databases: OVID
versions of MEDLINE and EMBASE, and The Cochrane
Library, from inception to July 2014. Given that there
are many conference presentations in this area, we cor-
responded with authors and further searched in Google
Scholar and other databases to check for pending or
recently published full articles. The search also covered
various sources of ‘grey literature’ to identify published,
unpublished and ongoing studies (see online supple-
mentary protocol-S). Further searches included the ref-
erence lists of relevant articles and books, citation
indexes and hand-search of issues in relevant journals.
There were no date or language restrictions on the
searches.
The following Medical Subject Headings (MESH)
terms and text words were used: pulmonary embolism.
tw., exp Pulmonary Embolism/, exp Venous
Thromboembolism/, prognos*.tw., exp Prognosis/,
predict*.tw., cohort stud*.tw, exp Cohort Studies/,
course.tw., exp Incidence/, score.tw., model*.tw., index.
tw., rule.tw., criteria.tw., tool*.tw., severity index*.tw.,
geneva.tw., davies.tw. These were combined as shown in
online supplementary box-s.
Data collection
Selection strategy
Potentially eligible studies were identiﬁed by examining
titles and abstracts or other summaries as available. Full
articles were obtained to assess eligibility criteria, before
critical appraisal. Study identiﬁcation was performed
by two independent and blinded assessors to avoid
selection bias. Disagreements were resolved through
discussion.
Data extraction content
The data extraction form (online supplementary
protocol-S) had six detailed sections: information about
the review and veriﬁcation of study eligibility, informa-
tion about the study, assessment of study quality, assess-
ment of methods relevant to the development phase of
the model, general ﬁndings and results of model
performance.
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Data extraction management
An electronic data collection form was created in Excel.
An explanation for the data extraction items was avail-
able in corresponding cells, but there were no coding
instructions. Contents were adjusted throughout the
data extraction process. Data were extracted by one
reviewer and checked by a second reviewer to obtain
reliable information on study ﬁndings and study meth-
odology. Disagreements were resolved by discussion.
Dealing with missing data
Study investigators were contacted by email for details
not reported in the published reports. A standard data
collection form was used to assist with this, when
needed.
Assessment of study quality
All studies were assessed for methodological quality10 13–18
and risk of bias in regard to study design, analysis and
reporting according to predeﬁned criteria for type of
study, sample of patients (proper formation of inception
cohort, description of referral pattern), adequacy of prog-
nostic factors, adequacy of outcome measures, blind assess-
ment of outcomes, completeness of follow-up, sample size,
treatment, missing data and adjustment for all potential
confounders (online supplementary protocol-S).
Summary scores were not used to identify studies of
high quality or low quality,17 19 but ‘risk of bias’ ﬁgures
were produced to show the ﬁndings graphically.
Data analysis
The descriptive analysis addressed reporting on type and
phase of development of the model, study character-
istics, population and setting patterns, patient character-
istics, prognostic information, prognostic modelling and
other data analyses, and study quality.
Quantitative analyses were performed at each relevant
model risk cut-off level for various outcomes and time
points. These used data from model validation and
model update studies, with and without the results of
the model construction study. Outcomes were all-cause
mortality, PE-related mortality, VTE recurrence, major or
clinically relevant bleeding and composite outcomes.
These were assessed for the duration of hospitalisation,
at 1 and at 3 months. Summary estimates and their 95%
CIs were calculated for the population event rates, for
the proportion of patients in risk categories and the inci-
dence of events within risk categories, and were
obtained as weighted average by the inverse variance
method. When data were available from at least four
studies, summary estimates of sensitivity and speciﬁcity
and summary receiver operating characteristic (sROC)
curves were obtained using the bivariate random-effects
model.20 21
Studies that compared models either within the same
article or in different articles or shared the same cohort
in various model development phases were included
once for the analysis of population event rates but as
often as the number of prognostic models that were
assessed for the analysis of risk group distribution, the
incidence of events within risk groups and the prognos-
tic performance of a model. Homogeneity of study
designs, differences because of the case mix and statis-
tical heterogeneity (Cochran’s Q test, Higgins I2 statistic)
were assessed to decide whether to combine the results
of individual studies. When results were combined, a
ﬁxed-effects or a random-effects model was used
depending on whether the effect was similar or variable
across studies. The likely inﬂuence of the presence or
absence of bias was examined in sensitivity analyses and
funnel plots (observed and imputed studies, Egger’s
regression intercept). Subgroup analyses were per-
formed for ‘stable’ and ‘both stable and unstable’ PE
patient groups, ‘prospective’ or ‘retrospective’ studies
and with regard to the phase of development (deriv-
ation, internal validation and external validation/
update) of studies.
Analysis was performed using metandi22 and
GLLAMM23 modules in Stata/SE (V.13.1), and using
Comprehensive Meta-Analysis (CMAV.2. 2.064).
Data synthesis
To decide whether a prognostic model would be helpful
for clinical practice, the following factors were required
in external validation studies: direction and size of
effect, and effect consistency across studies in the
meta-analysis; and strength of evidence for the effect
based on study quality and statistical measure of uncer-
tainty.17 For a valid model to be acceptable, its utility
should ideally have been demonstrated in an impact
study, such as in a one-arm management study using the
model or in a randomised trial comparing outcomes for
patients in whom the model is used to inform decision-
making and those for whom it is not used.
RESULTS
Search results
Figure 1 shows the ﬂow of studies through the review
following Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines.24 The
numbers of potentially relevant records identiﬁed and
screened in each database were 3127 in MEDLINE,
5819 in EMBASE and 1000 in The Cochrane Library.
Most of these were not eligible because they were
clearly not relevant (2711, 5276 and 945, respectively)
or because they did not meet selection criteria (328,
459 and 51, respectively). From 176 publications that
were retained from these databases (88, 84 and 4,
respectively) and from 10 additional publications from
other sources, 75 were removed as duplicate records
that had been found in more than one database and 40
were excluded for various reasons (ﬁgure 1): unmet cri-
teria,25–48 duplicate,49–52 selective population,53–56
journal club,57–59 comment letter,60 algorithm,61 long-term
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outcome,62 reliability study63 and very old variables in
the model.64
Finally, 71 studies were included in the review, 62 from
databases65–126 and 9 from other sources that were
mainly lists of references.127–135 Among studies included
from databases, most were in MEDLINE and EMBASE,
but four studies were not found in MEDLINE76 80 95 102
and one study was not in EMBASE.77 Two studies were
identiﬁed in The Cochrane Library,71 100 but these were
also found in MEDLINE and EMBASE. Some studies
were based on retrospective analysis of prospectively col-
lected data from previous diagnostic studies,136–141
one137 of which was used in two model construction
studies68 69 and two external validation studies.70 97
In total, among the 71 studies, 64 were found to be
including variables speciﬁc to the domain of PE and its
prognosis: 17 were identiﬁed as model construction
studies,65 67–69 85 87 89 90 92 110 118 121–124 129 135 41 as
model external validation or model update
studies70 72 74–78 80–84 86 88 91 93–97 99 101 102 104 106–109
111–117 119 120 127 130 131 134 and 6 as measuring model
impact.66 71 100 128 132 133 For the remaining seven studies,
variables in the model were either originally not speciﬁc
to PE98 103 105 or to its prognosis73 or concerned a hos-
pital checklist79 125 126 that is a combination of prognostic
and practical variables for outpatient management.
Descriptive analysis
Prognostic models
We identiﬁed three types of models related to risk strati-
ﬁcation of patients with PE (table 1 and see online sup-
plementary table S1). Type 1 model includes variables
speciﬁc to the domain and the prognosis of PE. Type 2
applies models that are used in other domains such as
the Global Registry of Acute Coronary Events
(GRACE)103 or the Charlson Comorbidity Index,98 105
or applies diagnostic prediction rules73 for the assess-
ment of PE prognosis. Type 3 models incorporate hos-
pital checklist variables as exclusion criteria from early
discharge or home treatment.79 125 126
Figure 1 Flow chart of search
results.
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Table 1 Variables used in the original prognostic models—prognostic variables included in the final models (only type 1 prognostic models presented) and points assigned (in numbers) to each variable when applied. Rule stands for scoring rule, score for
simplified scoring rule or scoring system
Models GPS
No
acronym
(Polish
model) PESI
PE
Prognostic
Algorithm
No
acronym
(Spanish
model)
No
acronym
(Dutch
model) EMEP
No
acronym
(Japanese
model)
No
acronym
(Chinese
model)
Simplified
PESI PREP UPS
No
acronym
Simple Score
FAST SIRS-WCC
No
acronym
eStiMaTe
(PROTECT)
Model construction
studies (derivation
samples)
(Wicki
et al122)
(Kostrubiec
et al90)
(Aujesky
et al68)
(Aujesky
et al69)
(Uresandi
et al118)
(Agterof
et al67)
(Volschan
et al121)
(Yamaki
et al123)
(Zhu
et al124)
( Jimenez
et al85)
(Sanchez
et al110)
(Agterof
et al65)
(Huang
et al129)
(Lankeit
et al92) and
(Dellas et al80)
( Jo
et al89)
(Bova
et al135)
(Jiménez
et al87)
N of candidate variables 14 NR 29 29 >30 7 20 16 NR 11 >30 7 38 NR NR Unclear 13
N of variables in final
model
6 2 11 10 7 2 5 7 8 6 5 4 4 3 4 4 4
Proposed risk
assessment method
Score Rule Score Rule Score Rule Score Score Equation Score Score Rule Score Score None Score Calculator
Type of selected
variables in final model
Total
N*
Demographic and clinical characteristics
Age 6 Age, in
year
x 1 3 1 x
Gender (male sex) 2 10 2
Syncope 2 x 1.5
Leg symptoms 1 1
Immobilisation/bed
rest
2 2 2
No recent surgery 1 1
Active cancer 8 2 30 x 2 1 6 x x
Metastatic cancer 1 4
Non-metastatic cancer 1 2
Previous DVT/PE 2 1 2
Heart failure 3 1 10 x
Chronic lung disease 3 10 x x
Chronic cor pulmonale 1 4
Heart failure or
chronic lung disease
2 1 x
Chronic renal disease 1 x
Cerebrovascular
disease
1 x
Recent bleeding 1 4
Inadequate
anticoagulation
1 1
Clinical findings
Cardiogenic shock 2 6 x
HR 12 20 x x 2 x 1 x x 2 x 1 x
SBP 6 2 30 x 1 2 x
RR 3 20 2 x
Temperature 2 20 x
Altered mental status 4 60 x 10 x
PaO2/SpO2 5 1 20 x 1 x
Accentuation of P2 1 x
Laboratory findings
WCC 3 x x x
Creatinine 1 3
CPK 1 x
cTnI 1 x
cTnT 1 x
hscTn 0
cTn 1 2
Continued
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Among the 17 ‘type 1’ prognostic models that were
identiﬁed in model construction studies,
868 69 85 87 92 110 118 122 underwent external validation or
were updated; some of them in many studies.
Three68 118 122 were assessed in impact studies.71 100 128
There are two other models that were tested in impact
studies,66 132 without being previously reported in a con-
struction study. Table 1 shows that the variables that were
mostly included in ﬁnal models were in descending
order: heart rate, active cancer, age, SBP, peripheral
oxygen saturation and altered mental status.
Most of the studies identiﬁed for this review were
external validation or update studies.
Study characteristics
Research objective, type of study and study design,
setting, country, number of participating centres,
patients (age, sex and haemodynamic status), outcomes,
time points and corresponding event rates are displayed
in online supplementary tables S2.1–S2.5.
In model construction studies (n=17) (see online sup-
plementary table S2.1), the objective was usually to risk-
stratify patients (13 studies) rather than to identify
low-risk patients. Nine studies were prospective, seven
reported on stable PE subgroup and seven were pro-
spective and concerned stable PE as well. In 8 studies,
patients were recruited in emergency departments
(EDs) and in 13 studies, inception started on admission.
Nine were multicenter studies. The PE Severity Index
(PESI)68 and Prognostic Algorithm69 cohort included
the largest derivation and internal validation sets, but
the study was retrospective, had missing data and lack of
information on PE diagnosis and on the type of treat-
ment received. Four studies87 110 121 135 were sound
methodologically and clinically relevant and present the
following characteristics: prospective multicenter study,
inception on admission, patients from ED, patients with
stable PE reported, adequate early outcome and time
point.
In model external validation studies (n=36) (see
online supplementary table S2.2), the main objective
was to identify low-risk patients. The other objectives
were to assess added value of prognostic variables,
head-to-head comparison or identiﬁcation of patients
with stable PE at high risk. Among the prospective
studies (n=9) in stable and unstable PE, one study102
validated the European Society of Cardiology (ESC)
model in terms of 30-day mortality and the other one
compared Hestia checklist criteria with simpliﬁed PESI
(sPESI) in terms of 7-day, 30-day and 3-month death; in
stable PE, Geneva prognostic score (GPS),74 PESI,104 111
sPESI,80 101 ESC,72 80 FAST80 and eStiMaTe87 models
were validated in seven studies, of which one study80
compared three models FAST, sPESI and ESC. Reliability
was also assessed in two studies.75 106
Model update studies (n=15) (see online supplemen-
tary table S2.3) assessed the value of adding a two-test or
a three-test strategy to PESI, based on a combination of
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RVD, cardiac troponin I (cTnI) and ultrasound
(US)-detected DVT, to identify patients with high-risk
PE;86 assessed the additive value of CT-RVD to Hestia,126
the additive value of transthoracic echocardiography
(TTE)-RVD,111 brain natriuretic peptide (BNP)111 or
cTnI to PESI,104 111 or TTE-RVD and BNP to Facteurs
PRonostiques dans l’Embolie Pulmonaire (PREP),110 or
the additive value of cardiac troponin T (cTnT),101 high-
sensitive cTnT94 101 or N-terminal proBNP
(NT-proBNP)95 to sPESI, in order to identify patients at
lower risk or at higher risk; or assessed the effect of
cause of death classiﬁcation on sPESI whether combined
or not to cTnI.109 Eight studies were prospective and spe-
ciﬁc to stable PE. Retrospective studies assessed the addi-
tive value of CT-RVD,112 of white cell count (WCC) and
systemic inﬂammatory response syndrome (SIRS),89 of
NT-proBNP, cTnI or CT-RVD77 to PESI; the additive
value of cTn to PESI96 or to sPESI;115 and the additive
value of TTE-RVD to Shock Index.117
Six studies measured model impact (see online supple-
mentary table S2.4). Four were performed in patients
identiﬁed as low risk by the model, assessing the safety of
early discharge or outpatient treatment. This was done
in a one-arm management study for GPS128 and
NT-proBNP,66 and in a randomised controlled trial
(RCT) where outpatient management was compared
with standard hospitalisation (inpatient treatment)
either by using the Spanish model100 or by using PESI in
the Outpatient Treatment of Pulmonary Embolism
(OTPE) study.71 The Pulmonary EmbolIsm
THrOmbolysis (PEITHO) randomised double-blind
trial132 assessed the role of ﬁbrinolytic therapy tenecte-
plase in normotensive patients with PE considered at
intermediate–high risk by TTE-RVD or CT-RVD, and
myocardial injury as indicated by a positive test for cTnI
or cTnT. Another study assessed the use and the impact
of model-based risk stratiﬁcation on treatment decisions
and outcome in clinical practice.133 All studies were mul-
ticenter and prospective except the latter, which was a
single-centre and retrospective study.
Study quality
Quality of individual studies and a summary of study
quality at different model development phases are
shown in online supplementary ﬁgures S1.1 to S6.2.
Among model construction studies (see online supple-
mentary ﬁgures S1.1 and S1.2), PREP,110 esTiMaTe87
and Bova’s study135 models satisﬁed most of the study
quality criteria. Criteria that were often met (in at least
70% of the included studies) are: inclusion criteria def-
inition, characteristics description, length of follow-up
and criteria about the outcome (objectiveness, full def-
inition, appropriateness, proportion of patients with
known outcome). Criteria that were least often met (in
<30% of the included studies) are: sample completeness
(selection bias), reasons for lost to follow-up reporting,
similarity of outcome assessment for all study partici-
pants, differences with participants who did not
complete the study, availability of prognostic variables
and justiﬁcation of sample size.
In model validation studies (see online supplementary
ﬁgures S2.1 and S2.2), including those that also updated
the model, the most recent validation studies87 101 102 111
satisﬁed most of the study quality criteria. The most
often met criteria concerned speciﬁcation of inclusion
criteria, sample selection, population characteristics
description, follow-up, outcome (objective, fully deﬁned,
appropriate, known for a high proportion of patients),
and full deﬁnition of prognostic variables and descrip-
tion of treatment. Major concerns were about sample
completeness, reporting on reasons for lost to follow-up
and differences with participants who did not complete
the study, justiﬁcation of sample size and statistical
analysis.
In model update studies (see online supplementary
ﬁgures s3.1 and s3.2), three studies95 101 111 satisﬁed
most of the criteria. The summary of study quality shows
that most of the criteria were often met, but there are
concerns about sample completeness and reporting on
reasons for lost to follow-up and differences with partici-
pants who did not end the study, justiﬁcation of sample
size and how lost to follow-up treated.
Model impact studies (see online supplementary
ﬁgures S4.1 and S4.2) had the best compliance with
study quality criteria, with most of the key factors
provided.66 71 100 132
For type 2 and 3 studies, the number of studies is too
small to draw general conclusions. In type 2 studies (see
online supplementary ﬁgures S5.1 and S5.2), although
inclusion was well deﬁned, there are problems with
sample selection and sample completeness in
all98 103 105 but one study,73 in justiﬁcation of sample size
and data analysis. In type 3 studies (see online supple-
mentary ﬁgures S6.1 and S6.2), the main concerns are
about a lack of information on reasons for lost to
follow-up, justiﬁcation of sample size and data analysis
(missing data, lost to follow-up, statistical adjustment).
Quantitative analysis
Population event rates
There were a total of 44 298 patients if patients in the
cohorts account once, only regardless of how many
studies reported those patients, and if impact studies
that involved only low-risk or intermediate-risk patients
are excluded.
Analysis based on inverse-variance method with
random-effects model (see online supplementary table
S3) showed overall in-hospital, 30-day and 3-month point
estimate to be 6.5% (95% CI 4.9% to 8.5%) (20
studies), 7.4% (6.5% to 8.5%) (32 studies) and 6.8%
(5.7% to 8.1%) (11 studies), respectively, for mortality;
3.1% (2.6% to 3.8%) (7 studies), 4.0% (3.2% to 5.0%)
(15 studies) and 2.9% (2.2% to 3.7%) (6 studies),
respectively, for PE-related mortality; and 0.2% (0.0% to
1.5%) (3 studies), 1.1% (0.7% to 1.8%) (6 studies) and
2.6% (1.6% to 4.4%) (4 studies), respectively, for VTE
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recurrence. Composite event rates, major and non-major
clinically relevant bleeding and fatal bleeding are also
displayed.
Risk groups
All-cause mortality
The distribution of risk groups for a model (proportion
of patients in low-risk or in high-risk groups) according
to speciﬁed cut-off levels and the incidence of all-cause
mortality within risk groups, expressed in % (95% CI),
are shown in detail (table 2). The following paragraphs
summarise the ﬁndings.
For GPS3 vs GPS≤2 cut-off, mortality was reported
only in a single external validation study; the prevalence
of the low-risk group is 82% (77.3% to 85.9%), and the
incidence of 30-day mortality in the low-risk group is
9.8% (3.2% to 26.6%). The prevalence of high-risk
group is 18% (14.1% to 22.7%) and the incidence of
30-day mortality is 20.1% (11.4% to 33%).
For PESIIII vs PESI≤II cut-off, the overall prevalence
of low-risk group is 43.1% (39.6% to 46.6%) and the
overall in-hospital, 30-day and 3-month mortality rates
within low-risk group are 1.4% (1.2% to 1.8%) (5
studies), 2.3% (1.7% to 2.9%) (9 studies) and 1% (0.5%
to 1.8%) (6 validation studies), respectively. The overall
prevalence of high-risk patients is 56.9% (53.4% to
60.4%) and the overall in-hospital, 30-day and 3-month
mortality rates are 9.3% (8.4% to 10.4%), 11.4% (9.9%
to 13.1%) and 13.0% (8.7% to 18.9%), respectively.
Summary estimate of the prevalence and the mortality
rates from external validation studies are consistent with
those of the derivation and internal validation samples.
For sPESI, the overall prevalence of low-risk group is
36.3% (33.3% to 39.4%). The overall in-hospital, 30-day
and 3-month mortality rates are 0.3% (0% to 2.3%) (2
external validation studies), 1.5% (0.9% to 2.5%) (11
studies) and 0.8% (0.3% to 2.2%) (3 external validation
studies), respectively. The overall proportion of high-risk
patients is 63.7% (60.6% to 66.7%) and the overall
in-hospital, 30-day and 3-month mortality rates are 3.2%
(1.6% to 6.4%), 10.7% (8.8% to 12.9%) and 13.6%
(8.8% to 20.3%), respectively. Results are consistent
across derivation, internal validation and external valid-
ation samples.
With the algorithm (4 studies), 22% (19.3% to 24.9%)
of patients are classiﬁed as low risk. The in-hospital and
30-day mortality rates are 0.6% (0.4% to 1%) and 1.1%
(0.5% to 2.1%), respectively. The results in the valid-
ation and the derivation samples are similar.
For the PREP model (mortality reported in 1 external
validation study), 67.2% (61.7% to 72.3%) of patients
are classiﬁed as low risk. The 30-day and 3-month mor-
tality rates are 1% (0.2% to 3.9%) and 1.5% (0.5% to
4.5%), respectively, in the low-risk group, and 7.1%
(3.4% to 14.1%) and 9.1 (4.8 to 16.6), respectively, in
the high-risk group. In the original study, the incidence
of a 30-day composite outcome is 2.5% (1.2% to 4.9%),
37.3% (33.2% to 41.5%) of patients are classiﬁed as
high risk and the incidence of events is 17.7% (12.9% to
23.8%).
Shock Index classiﬁes 80.3% (68% to 88.7%) of
patients in the low-risk group, but with a high 30-day
mortality rate of 10.7% (6.1% to 17.9%) and 24.1%
(13.6% to 39.1%) in the high-risk group.
With ESC, the low-risk group prevalence is 89.8%
(72.7% to 96.7%); the in-hospital and 30-day mortality
rates are 5% (3.6% to 7.1%) (3 studies) and 8.9% (4.7%
to 16.5%) (1 study), respectively, in the low-risk group,
and 41.1% (22.7% to 62.5%) and 26.5% (16.1% to
40.4%), respectively, in the high-risk group. These
results apply for ‘both stable and unstable’ patients. For
the stable PE patient subgroup, for ‘intermediate–high’
risk cut-off (intermediate–high-risk patients have RVD
and myocardial injury, and the lower risk that includes
intermediate–low-risk and low-risk groups either one of
them or none), the proportion of the lower risk group is
74.4% (52.4% to 88.5%) (5 studies) and the in-hospital
mortality rate is 3.1% (1.4% to 6.8%) in the lower risk
group and 7.7% (4.7% to 12.2%) in the intermediate–
high-risk group.
Given the high event rate within the ‘low-risk’ groups
from Shock Index and ESC, these would not qualify as
suitable for the identiﬁcation of a low-risk but of a ‘high-
risk’ patient group.
The performance of other models recently con-
structed is discussed in model update section.
Outcomes other than all-cause mortality
Tables 3 and 4 show summary estimates with results
from studies that report outcomes in terms of PE-related
death, adverse outcome (clinical deterioration, haemo-
dynamic collapse), VTE and their combinations in ‘both
stable and unstable’ (table 3), and separately in ‘stable’
(table 4) patient groups. Although many studies were
retrospective or were single studies, the results conﬁrm
the predictive ability for PESI and sPESI at the optimal
cut-offs or less, preferably in combination with biomar-
kers, for identifying patients at low risk for these speciﬁc
outcomes as well, mainly in stable PE. They also conﬁrm
the ability for some models at higher cut-offs for identi-
fying patients at very high risk (30-day event rate over
20%) such as PREP—ClinIII without or with BNP—
TTE-RVD, PESIIV, PESI V without or with TTE-RVD,
ESC high, Shock Index, eStiMaTe high, FAST 3, Bova
stage III. Most of the models combine biomarkers or
imaging-based modalities to clinical variables or to pre-
existing models. In most of the studies, the proportion
of patients at very low or at very high risk is low.
Type 2 and type 3 model studies
Table 5 shows the results of type 2 and type 3 model
studies. Revised Geneva score73 (RGS) and simpliﬁed
Geneva score73 (SGS) originally dedicated for the diag-
nosis of PE may provide at low cut-offs a small 3-month
mortality rate (0.9% (0.1% to 12.3%)) in patients at low
risk. Similarly, at the lowest cut-offs, GRACE ACS103 and
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Table 2 In-hospital, 30-day and 3-month all-cause mortality, and distribution of risk groups for relevant risk cut-offs
Outcome time point
Prognostic model
Cut-off—risk groups
Prevalence of risk groups
N (%) (95% CI)
Incidence of events within risk groups
N (%) (95% CI)
Derivation Internal validation External validation Overall Derivation Internal validation External validation Overall
In-hospital mortality GPS-3 1 1
High (18.9) (14.1 to 24.9) 7.9 (2.6 to 21.8)
Low (81.1) (75.1 to 85.9) 0.6 (0.1 to 4.2)
PESI-III 1 1 3 5 1 1 3 5
High (59.1) (58.1 to 60) (59.3) (57.9 to 60.6) (55.8) (41 to 69.7) (58.4) (55.1 to 61.6) (8.8) (8.1 to 9.5) (9.8) (8.8 to 10.9) (9.8) (6.5 to 14.4) (9.3) (8.4 to 10.4)
Low (40.9) (40 to 41.9) (40.7) (39.4 to 42.1) (44.2) (30.3 to 59) (41.6) (38.4 to 44.9) (1.3) (1 to 1.7) (1.5) (1.1 to 2.1) (2.2) (1 to 4.7) (1.4) (1.2 to 1.8)
sPESI 2 2
High (53.9) (29.2 to 76.8) (3.2) (1.6 to 6.4)
Low (46.1) (23.2 to 70.8) (0.3) (0 to 2.3)
Algorithm 1 1 2 4 1 1 2 4
High (78.4) (77.6 to 79.2) (78.4) (77.3 to 79.5) (76.1) (55.1 to 89.2) (78) (75.1 to 80.7) (5.2) (4.7 to 5.7) (6.1) (5.4 to 6.9) (3.6) (0.7 to 16.2) (5.8) (4.8 to 7)
Low (21.6) (20.8 to 22.4) (21.6) (20.5 to 22.7) (23.9) (10.8 to 44.9) (22) (19.3 to 24.9) (0.4) (0.2 to 0.8) (0.9) (0.5 to 1.7) (0.6) (0.1 to 3.1) (0.6) (0.4 to 1)
ESC 3 3
High (10.2) (3.3 to 27.3) (41.1) (22.7 to 62.5)
Low (89.8) (72.7 to 96.7) (5) (3.6 to 7.1)
Shock Index 1 1
High (17.4) (12.2 to 24.2) (22.2) (10.3 to 41.4)
Low (82.6) (75.8 to 87.8) (3.9) (1.6 to 9)
30-day mortality GPS-3 1 1
High (18) (14.1 to 22.7) (20.1) (11.4 to 33)
Low (82) (77.3 to 85.9) (9.8) (3.2 to 26.6)
PESI-III 1 1 7 9 1 1 7 9
High (59.1) (58.1 to 60) (59.3) (57.9 to 60.6) (56.1) (48.6 to 63.3) (56.9) (53.4 to 60.4) (14) (13.1 to 14.9) (14.2) (13.1 to 15.5) (9.8) (8.0 to 11.9) (11.4) (9.9 to 13.1)
Low (40.9) (40 to 41.9) (40.7) (39.4 to 42.1) (43.9) (36.7 to 51.4) (43.1) (39.6 to 46.6) (2.1) (1.8 to 2.6) (2.6) (2 to 3.3) (1.8) (1.0 to 3.2) (2.3) (1.7 to 2.9)
sPESI 1 10 11 1 10 11
High (69.3) (66.4 to 72.1) (63.1) (59.8 to 66.3) (63.7) (60.6 to 66.7) (10.9) (8.8 to 13.4) (10.6) (8.6 to 13) (10.7) (8.8 to 12.9)
Low (30.7) (27.9 to 33.6) (36.9) (33.7 to 40.2) (36.3) (33.3 to 39.4) (1) (0.3 to 3) (1.6) (0.9 to 2.7) (1.5) (0.9 to 2.5)
PREP Clin—II 1 1
High (32.8) (27.7 to 38.3) (7.1) (3.4 to 14.1)
Low (67.2) (61.7 to 72.3) (1) (0.2 to 3.9)
Algorithm 1 1 2 4 1 1 2 4
High (78.4) (77.6 to 79.2) (78.4) (77.3 to 79.5) (76.1) (55.1 to 89.2) (78) (75.1 to 80.7) (11.5) (10.8 to 12.2) (11.7) (10.7 to 12.7) (7.9) (2.5 to 22.4) (11.6) (10.4 to 12.9)
Low (21.6) (20.8 to 22.4) (21.6) (20.5 to 22.7) (23.9) (10.8 to 44.9) (22) (19.3 to 24.9) (0.6) (0.3 to 1) (1.5) (0.9 to 2.4) (1.6) (0.6 to 4.5) (1.1) (0.5 to 2.1)
ESC 1 1
High (10.1) (8 to 12.6) (26.5) (16.1 to 40.4)
Low (89.9) (87.4 to 92) (8.9) (4.7 to 16.5)
Shock Index 2 2
High (19.7) (11.3 to 32) (24.1) (13.6 to 39.1)
Low (80.3) (68 to 88.7) (10.7) (6.1 to 17.9)
3-month mortality GPS-3 2 2
High (18) (14.1 to 22.7) 23.6 (14.2 to 36.6)
Low (82) (77.3 to 85.9) 4.9 (2.8 to 8.4)
PESI-III 6 6
High (49.6) (43.3 to 56.0) (13.0) (8.7 to 18.9)
Low (50.4) (44.0 to 56.7) (1) (0.5 to 1.8)
sPESI 3 3
High (53.8) (39.4 to 67.6) (13.6) (8.8 to 20.3)
Low (46.2) (32.4 to 60.6) (0.8) (0.3 to 2.2)
PREP Clin=II 1 1
High (32.8) (27.7 to 38.3) (9.1) (4.8 to 16.6)
Low (67.2) (61.7 to 72.3) (1.5) (0.5 to 4.5)
ESC, European Society of Cardiology; GPS, Geneva prognostic score; N, number of studies; PESI, Pulmonary Embolism Severity Index; PREP, Facteurs PRonostiques dans l’Embolie
Pulmonaire; sPESI, simplified PESI.
Elias
A,etal.BM
J
Open
2016;6:e010324.doi:10.1136/bm
jopen-2015-010324
9
O
p
e
n
A
c
c
e
s
s
 on 31 May 2018 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2015-010324 on 29 April 2016. Downloaded from 
Table 3 PE-related death, adverse outcome (death, clinical deterioration or haemodynamic collapse), VTE, major bleeding and their combinations in ‘both stable and
unstable’ PE patient risk groups
Risk cut-off (author, year)
Development
phase
N
studies
Type of
study
Haemodynamic
status Outcome
Time
point
Proportion
(95% CI)
High-risk group
Low-risk group
Event rate
(95% CI)
High-risk group
Low-risk group
Algorithm1
( Jakobsson et al 2010)130 External
validation
1 Retrospective Not reported PE-related death 30 days 83.7 (81.3 to 85.9)
16.3 (14.1 to 18.7)
6.6 (5.1 to 8.5)
0.6 (0.1 to 4.3)
Agterof (Herat rate—Ddimer)
(Agterof et al 2009)67 Derivation 1 Retrospective Both stable and
unstable
Death VTE major
bleeding
In-hospital 67.1 (61.7 to 72.1)
32.9 (27.9 to 38.3)
5.3 (3.0 to 9.3)
0.5 (0 to 7.3)
ESC high
(Vanni et al 2011)119 External
validation
1 Retrospective Both stable and
unstable
PE-related death In-hospital 5.6 (3.8 to 8)
94.4 (92 to 96.2)
29.6 (15.6 to 49)
4.1 (2.7 to 6.4)
ESC intermediate–high
(Vanni et al 2011)119 External
validation
1 Retrospective Both stable and
unstable
PE-related death In-hospital 60 (55.6 to 64.3)
40 (35.7 to 44.4)
8.6 (5.9 to 12.4)
1 (0.3 to 4)
GPS1
(Wicki et al 2000)122 Derivation 1 Retrospective Not reported Death VTE major
bleeding
3 months 80.6 (75.4 to 84.9)
19.4 (15.1 to 24.6)
12.5 (8.7 to 17.6)
0.9 (0.1 to 13.4)
(Nendaz et al 2004)97 External
validation
1 Retrospective Unclear Death VTE major
bleeding
3 months 71.4 (64.7 to 77.2)
28.6 (22.8 to 35.3)
12.0 (7.6 to 18.4)
3.5 (0.9 to 13.0)
Overall 2 Death VTE major
bleeding
3 months 76.3 (66.1 to 84.2)
23.7 (15.8 to 33.9)
12.3 (9.3 to 16.1)
2.7 (0.8 to 8.9)
GPS2
(Wicki et al 2000)122 Derivation 1 Retrospective Not reported Death VTE major
bleeding
3 months 51.1 (45.1 to 57.1)
48.9 (42.9 to 54.9)
18.2 (12.6 to 25.6)
1.5 (0.4 to 5.9)
(Nendaz et al 2004)97 External
validation
1 Retrospective Unclear Death VTE major
bleeding
3 months 44.2 (37.5 to 51.2)
55.8 (48.8 to 62.5)
18.2 (11.4 to 27.6)
2.7 (0.9 to 8.0)
Overall 2 Death VTE major
bleeding
3 months 47.9 (41.2 to 54.7)
52.1 (45.3 to 58.8)
18.2 (13.7 to 23.8)
2.1 (0.9 to 51)
GPS3
(Wicki et al 2000)122 Derivation 1 Retrospective Not reported Death VTE major
bleeding
3 months 32.8 (27.5 to 38.7)
67.2 (61.3 to 72.5)
26.1 (18.0 to 36.3)
2.2 (0.8 to 5.8)
(Nendaz et al 2004)97 External
validation
Retrospective Unclear Death VTE major
bleeding
3 months 20.1 (15.1 to 26.2)
79.9 (73.8 to 84.9)
27.5 (15.9 to 43.2)
5.0 (2.5 to 9.7)
Overall 2 Death VTE major
bleeding
3 months 26.2 (15.6 to 40.5)
73.8 (59.5 to 84.4)
26.6 (19.6 to 34.9)
3.6 (1.6 to 7.8)
GPS4
(Wicki et al 2000)122 Derivation 1 Retrospective Not reported Death VTE major
bleeding
3 months 11.9 (8.6 to 16.4)
88.1 (83.6 to 91.4)
40.6 (25.3 to 58.1)
5.9 (3.5 to 9.8)
(Nendaz et al 2004)97 External
validation
1 Retrospective Unclear Death VTE major
bleeding
3 months 8.0 (5.0 to 12.7)
92.0 (87.3 to 95.0)
31.3 (13.6 to 56.7)
7.7 (4.6 to 12.5)
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Table 3 Continued
Risk cut-off (author, year)
Development
phase
N
studies
Type of
study
Haemodynamic
status Outcome
Time
point
Proportion
(95% CI)
High-risk group
Low-risk group
Event rate
(95% CI)
High-risk group
Low-risk group
Overall 2 Death VTE major
bleeding
3 months 10.2 (6.9 to 14.7)
89.8 (85.3 to 93.1)
37.6 (25.1 to 52)
6.7 (4.7 to 9.6)
GPS5
(Wicki et al 2000)122 Derivation 1 Retrospective Not reported Death VTE major
bleeding
3 months 3.7 (2.0 to 6.8)
96.3 (93.2 to 98.0)
70.0 (37.6 to 90.0)
7.8 (5.1 to 11.7)
(Nendaz et al 2004)97 External
validation
1 Retrospective Unclear Death VTE major
bleeding
3 months 2.5 (1.0 to 5.9)
97.5 (94.1 to 99.0)
80.0 (30.9 to 97.3)
7.7 (4.7 to 12.4)
Overall 2 Death VTE major
bleeding
3 months 3.3 (2.0 to 5.4)
96.7 (94.6 to 98.0)
73.0 (46.1 to 89.5)
7.7 (5.6 to 10.6)
GPS=6
(Wicki et al 2000)122 Derivation 1 Retrospective Not reported Death VTE major
bleeding
3 months 1 (0.4 to 3.4)
98.9 (96.6 to 99.6)
87.5 (26.6 to 99.3)
9.1 (6.1 to 13.2)
(Nendaz et al 2004)97 External
validation
1 Retrospective Unclear Death VTE major
bleeding
3 months 1 0.5 (0.1 to 3.5)
99.5 (96.5 to 99.9)
NA
9.6 (6.2 to 14.6)
Overall 2 Death VTE major
bleeding
3 months 0.9 (0.3 to 2.4)
99.1 (97.6 to 99.7)
87.5 (26.6 to 99.3)
9.3 (7.0 to 12.3)
PESIII
(Aujesky et al 2007)70 External
validation
1 Retrospective Both stable and
unstable
PE-related death 3 months 79.5 (76.8 to 82)
20.5 (18 to 23.2)
2.9 (1.9 to 4.5)
0.3 (0 to 4.2)
PESIIII
(Vanni et al 2011)119 External
validation
1 Retrospective Both stable and
unstable
PE-related death In-hospital 68.7 (64.3 to 72.7)
31.3 (27.3 to 35.7)
7.5 (5.1 to 11)
0.7 (0.1 to 4.7)
(Aujesky et al 2007)70 External
validation
1 Retrospective Both stable and
unstable
PE-related death 3 months 52.6 (49.3 to 55.9)
47.4 (44.1 to 50.7)
3.8 (2.4 to 6)
0.7 (0.2 to 2.2)
PESIIV
(Choi et al 2014)77 External
validation
1 Retrospective Both stable and
unstable
Adverse outcome In-hospital 18 (15.3 to 21.2)
82 (78.8 to 84.7)
24.8 (17.8 to 33.4)
7.3 (5.4 to 9.9)
(Aujesky et al 2007)70 External
validation
1 Retrospective Both stable and
unstable
PE-related death 3 months 25 (22.3 to 28)
75 (72 to 77.7)
6.7 (4.1 to 10.8)
0.9 (0.4 to 2)
PESI=V
(Aujesky et al 2007)70 External
validation
1 Retrospective Both stable and
unstable
PE-related death 3 months 10.3 (8.5 to 12.5)
89.7 (87.5 to 91.5)
7.5 (3.6 to 15)
1.7 (1 to 2.9)
PESIIV and other prognostic factors*
(Choi et al 2014)77 External
validation
1 Retrospective Both stable and
unstable
Adverse outcome In-hospital
NT-proBNP1136 pg/mL 34.2 (29.7 to 39.0)
65.8 (61.0 to 70.3)
22.4 16.1 to 30.2)
4.7 (2.7 to 8.0)
cTnI0.05 ng/mL 39.1 (34.8 to 43.6)
60.9 (56.4 to 65.2)
21.6 (16.3 to 28.1)
5.2 (3.2 to 8.5)
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Table 3 Continued
Risk cut-off (author, year)
Development
phase
N
studies
Type of
study
Haemodynamic
status Outcome
Time
point
Proportion
(95% CI)
High-risk group
Low-risk group
Event rate
(95% CI)
High-risk group
Low-risk group
CT RV/LV diameter ratio1 36.1 (32.5 to 39.9)
63.9 (60.1 to 67.5)
20.1 (15.4 to 25.7)
5.1 (3.3 to 7.7)
PESIIV—NT-proBNP1136 pg/mL 6.2 (4.2 to 9.1)
93.8 (90.9 to 95.8)
50.0 (31.0 to 69.0)
8.0 (5.6 to 11.3)
PESIIV—cTnI0.05 ng/mL 10.3 (7.8 to 13.4)
89.7 (86.6 to 92.2)
41.7 (28.7 to 55.9)
8.1 (5.9 to 11.1)
PESIIV—CT RV/LV ratio1 7.9 (6.0 to 10.2)
92.1 (89.8 to 94.0)
43.1 (30.4 to 56.9)
7.7 (5.8 to 10.2)
PESIIV—NT-proBNP—cTnI 4.6 (2.9 to 7.3)
95.4 (92.7 to 97.1)
64.7 (40.4 to 83.2)
8.2 (5.8 to 11.6)
PESIIV—NT-proBNP—RV/LV 4.2 (2.6 to 6.7)
95.8 (93.3 to 97.4)
62.5 (37.7 to 82.1)
8.4 (6.0 to 11.7)
PESIIV—cTnI—RV/LV 6.0 (4.2 to 8.6)
94.0 (91.4 to 95.8)
60.7 (42.0 to 76.7)
8.5 (6.2 to 11.5)
PESIIV—NT-proBNP—cTnI—
RV/LV
3.8 (2.3 to 6.3)
96.2 (93.7 to 97.7)
71.4 (43.9 to 88.9)
8.5 (6.0 to 11.9)
PREP
(Sanchez et al 2010)110 Derivation 1 Prospective Both stable and
unstable
Death VTE 30 days
PREP—ClinII 37.3 (33.2 to 41.5)
62.7 (58.5 to 66.8)
17.7 (12.9 to 23.8)
1.9 (0.8 to 4.1)
PREP—ClinIII 7.2 (5.2 to 9.8)
92.8 (90.2 to 94.8)
43.2 (28.4 to 59.4)
5.4 (3.7 to 7.9)
PREP—ClinII—BNP—RVD 34.8 (30.8 to 39)
65.2 (61 to 69.2)
18.4 (13.4 to 24.8)
2.1 (1 to 4.3)
PREP—ClinIII—BNP—RVD 5.6 (3.9 to 8)
94.4 (92 to 96.1)
44.8 (28.1 to 62.8)
5.6 (3.8 to 8)
Shock Index
(Toosi et al 2008)117 External
validation
1 Retrospective Not reported Adverse outcome In-hospital 17.6 (12.4 to 24.5)
82.4 (75.5 to 87.6)
25.9 (12.9 to 45.3)
10.3 (6.1 to 17)
sPESI1
(Righini et al 2011)106 External
validation
1 Retrospective Unclear PE-related death 30 days 53.8 (48.6 to 58.9)
46.2 (41.1 to 51.4)
3.1 (1.4 to 6.8)
0.6 (0.1 to 4.2)
(Spirk et al 2011)115 External
validation
1 Retrospective Both stable and
unstable
Death VTE 30 days 70.8 (65.7 to 75.4)
29.2 (24.6 to 34.3)
8.1 (5.2 to 12.3)
1 (0.1 to 7)
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GRACE PE103 risk scores show 1.3% (0.1% to 17.1%)
and 1.1% (0.1% to 15.1%) 30-day mortality rate,
respectively, within the low-risk patient groups. Of note
is a large 95% CI for Geneva and GRACE scores due
the small number of patients in the low-risk groups.
Interestingly, the high event rates (23–30%) in the high-
risk groups of GRACE scores whatever the cut-offs with
a high proportion (49–81%) of patients in these risk
groups. These models need to be validated in prospect-
ive studies with larger sample sizes in stable PE. Davies79
and Hestia125 126 checklists (table 5 and online supple-
mentary table S2.5) show a high proportion of patients
at low risk (42–55%) with a small 3-month mortality
rate: 1.9% (0.4% to 5.5%) and 1.2% (0.4% to 3.7%),
respectively. These models need to be compared with
PESI/sPESI models in impact studies.
Incidence of events along the risk scale
As expected, the event rates for different outcomes and
time points increase along the risk scale. Tables 3–5
and online supplementary table S4 show how the pre-
dicted outcomes in the derivation samples compare
with the observed outcomes in the validation samples
(internal, external) at different cut-offs for GPS and
PESI. Shifting the cut-off to a lower level or to a higher
level provides more appropriate event rates in low-risk
groups and in high-risk groups, respectively, but at the
expense of a decrease in the proportion of patients
within these risk groups. Thus, improvement in efﬁcacy
is associated with a decline in efﬁciency.
Prognostic accuracy
Summary estimates are displayed (see online supple-
mentary tables S5 and S6) for different cut-offs as iden-
tiﬁed in studies to discriminate between low-risk and
high-risk groups. They are provided only when at least
four studies are identiﬁed for a speciﬁc cut-off, and a
speciﬁc outcome and time point. The highest overall
sensitivity estimates were obtained with the Prognostic
Algorithm (4 studies) for predicting in-hospital mortal-
ity (97% (96% to 98%)) and 30-day mortality (98%
(96% to 99%)), followed by PESI (94% (89% to 97%))
for 3-month mortality (6 external validation studies)
and by sPESI (93% (90% to 95%)) for 30-day (11
studies) and for 3-month mortality (10 external valid-
ation studies) (see online supplementary table S5). All
results are consistent and similar in external validation
studies. The same applies for LR negative estimates.
The speciﬁcity is at best 54% (46% to 62%) for
PESIIII cut-off for 3-month mortality. Shifting the
cut-off along the risk scale provides higher values for
sensitivity or for speciﬁcity (see online supplementary
table S6). In ﬁgures 2 and 3, sROC plots showing test
accuracy of the two most validated models at relevant
cut-offs PESIIII and sPESI1 associated with 30-day
all-cause death for all studies and for external validation
studies are given separately.
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Table 4 PE-related death, adverse outcome (death, clinical deterioration or haemodynamic collapse), VTE, major bleeding and their combinations in ‘stable’ PE patient
risk groups
Risk cut-off
(author, year)
Development
phase
N
studies Type of study
Haemodynamic
status Outcome
Time
point
Proportion
(95% CI)
High-risk group
Low-risk group
Event rate
(95% CI)
High-risk group
Low-risk group
Bova et al risk score
(Bova et al 2014)135 Derivation and
internal validation
6 (IPD) Both Stable
Stage III PE-related death,
collapse, VTE
In-hospital 5.8 28
Stage II 18.6 9.7
Stage I 75.5 3.6
Stage III PE-related death,
collapse, VTE
30 days 5.8 29.2
Stage II 18.6 10.8
Stage I 75.5 4.2
Stage III PE-related death 30 days 5.8 15.5
Stage II 18.6 5.0
Stage I 75.5 1.7
ESC intermediate
(Vanni et al 2011)119 External validation 1 Retrospective Stable PE-related death In-hospital 57.6 (53.1 to 62.1)
42.4 (37.9 to 46.9)
6.4 (4.0 to 10.1)
1.0 (0.3 to 4.0)
(Becattini et al 2013)72 External validation 1 Prospective Stable PE-related death In-hospital 78.3 (75.4 to 80.9)
21.7 (19.1 to 24.6)
1.8 (1.0 to 3.1)
0.3 (0.00 to 4.1)
Overall 1 Both Stable PE-related death In-hospital 68.9 (46.1 to 85.2)
31.1 (14.8 to 53.9)
3.4 (0.9 to 11.7)
0.8 (0.2 to 2.7)
(Dellas et al 2014)80 External validation 1 Prospective Stable Adverse outcome 30 days 78.1 (72.2 to 83.1)
21.9 (16.9 to 27.8)
10.9 (7 to 16.4)
1 (0.1 to 14.1)
ESC intermediate–high
(Vanni et al 2011)119 External validation 1 Retrospective Stable PE-related death In-hospital 14.8 (11.9 to 18.4)
85.2 (81.6 to 88.1)
11.8 (6.0 to 21.8)
2.8 (1.6 to 5.0)
(Becattini et al 2013)72 External validation 1 Prospective Stable PE-related death In-hospital 41.8 (38.5 to 45.1)
58.2 (54.9 to 61.5)
1.9 (0.9 to 4.0)
1.0 (0.4 to 2.4)
Overall 1 Stable PE-related death In-hospital 26.2 (8.2 to 58.7)
73.8 (41.3 to 91.8)
4.9 (0.8 to 25.1)
1.8 (0.6 to 4.8)
(Becattini et al 2013)72 External validation 1 Prospective Stable Death adverse
outcome
In-hospital 41.8 (38.5 to 45.1)
58.2 (54.9 to 61.5)
8.8 (6.3 to 12.2)
3.2 (1.9 to 5.1)
(Becattini et al 2013)72 External validation 1 Prospective Stable PE-related death
adverse outcome
In-hospital 41.8 (38.5 to 45.1)
58.2 (54.9 to 61.5)
5 (3.1 to 7.7)
2.4 (1.4 to 4.1)
eStiMaTe high
( Jiménez et al 2014)87 Derivation 1 Prospective Stable Death adverse
outcome VTE
30 days 3.7 (2.6 to 5.2)
96.3 (94.8 to 97.4)
25.8 (13.5 to 43.7)
3.4 (2.1 to 5.4)
( Jiménez et al 2014)87 External validation 1 Prospective Stable Death adverse
outcome
30 days 6.2 (4.5 to 8.6)
93.8 (91.4 to 95.5)
21.2 (10.5 to 38.3)
6.7 (5.2 to 8.7)
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Table 4 Continued
Risk cut-off
(author, year)
Development
phase
N
studies Type of study
Haemodynamic
status Outcome
Time
point
Proportion
(95% CI)
High-risk group
Low-risk group
Event rate
(95% CI)
High-risk group
Low-risk group
( Jiménezet al 2014)87 Overall 2 Prospective Stable Death adverse
outcome VTE
30 days 4.8 (2.8 to 8)
95.2 (92 to 97.2)
23.5 (14.7 to 35.4)
5 (2.5 to 9.4)
eStiMaTe high–intermediate
( Jiménez et al 2014)87 Derivation 1 Prospective Stable Death adverse
outcome VTE
30 days 74.5 (71.5 to 77.3)
25.5 (22.7 to 28.5)
9.7 (7.6 to 12.2)
0.9 (0.2 to 3.6)
( Jiménez et al 2014)87 External validation 1 Prospective Stable Death adverse
outcome
30 days 63.5 (59.3 to 37.5)
36.5 (32.5 to 40.7)
7.1 (4.8 to 10.4)
0.3 (0 to 4)
( Jiménez et al 2014)87 Overall 2 Prospective Stable Death adverse
outcome VTE
30 days 69.3 (57.6 to 79)
30.7 (21 to 42.4)
8.6 (6.5 to 11.4)
0.7 (0.2 to 2.4)
FAST=3
(Dellas et al 2014)80 External validation 1 Prospective Stable Adverse outcome 30 days 28.4 (23.4 to 34.1)
71.6 (65.9 to 76.6)
22.1 (14.2 to 32.7)
1.5 (0.5 to 4.7)
GPS3
(Bova et al 2009)74 External validation 1 Prospective Stable PE-related death In-hospital 18.9 (14.1 to 24.9)
81.1 (75.1 to 85.9)
2.6 (0.4 to 16.5)
0.3 (0.0 to 4.7)
Kostrubiec et al (NT-proBNP—cTnT)
(Kostrubiec et al
2005)90
Derivation 1 Prospective Stable
Intermediate Death 30 days 72.0 (62.4 to 79.9)
28.0 (20.1 to 37.6)
20.8 (13.0 to 31.7)
1.7 (0.1 to 22.3)
Intermediate PE-related death 30 days 69.9 (59.8 to 78.3)
30.1 (21.7 to 40.2)
12.3 (6.3 to 22.7)
1.7 (0.1 to 22.3)
Intermediate–high Death 30 days 18.0 (11.6 to 26.8)
82.0 (73.2 to 88.4)
50.0 (28.4 to 71.6)
7.3 (3.3 to 15.3)
Intermediate–high PE-related death 30 days 16.1 (1.0 to 25.0)
83.9 (75.0 to 90.0)
40.0 (19.2 to 65.2)
2.6 (0.6 to 9.7)
PESIII
(Sanchez et al 2013)111 External validation 1 Retrospective
(for PESI)
Stable Adverse outcome 30 days 75.2 (71.4 to 78.7)
24.8 (21.3 to 28.6)
6 (4.1 to 8.8)
0.8 (0 to 5.2)
PESIIII
(Palmieri et al 2008)104 External validation 1 Prospective Stable Death adverse
outcome
In-hospital 69.7 (59.4 to 78.3)
30.3 (21.7 to 40.6)
53.2 (40.9 to 65.2)
11.1 (3.6 to 29.3)
(Sanchez et al 2013)111 External validation 1 Retrospective
(for PESI)
Stable Adverse outcome 30 days 37.8 (33.8 to 42)
62.2 (58 to 66.2)
9 (5.7 to 13.8)
2.1 (1 to 4.4)
(Vanni et al 2011)119 External validation 1 Retrospective Stable PE-related death In-hospital 67 (62.3 to 71.3)
33 (28.7 to 37.7)
6.1 (3.8 to 9.5)
0.7 (0.1 to 5)
PESIIV
(Sanchez et al 2013)111 External validation 1 Retrospective
(for PESI)
Stable Adverse outcome 30 days 17.2 (14.2 to 20.7)
82.8 (79.3 to 85.8)
8.8 (4.5 to 16.6)
3.9 (2.4 to 6.2)
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Table 4 Continued
Risk cut-off
(author, year)
Development
phase
N
studies Type of study
Haemodynamic
status Outcome
Time
point
Proportion
(95% CI)
High-risk group
Low-risk group
Event rate
(95% CI)
High-risk group
Low-risk group
PESI=V
(Sanchez et al 2013)111 External validation 1 Retrospective
(for PESI)
Stable Adverse outcome 30 days 4 (2.6 to 6)
96 (94 to 97.4)
14.3 (4.7 to 36.1)
4.3 (2.9 to 6.5)
PESI+biomarkers
(Sanchez et al 2013)111 External validation 1 Retrospective
(for PESI)
Stable Adverse outcome 30 days
PESI I–II—BNP 32.7 (27.8 to 38.0)
67.3 (62.0 to 72.2)
4.7 (2.0 to 10.8)
0.9 (0.2 to 3.6)
PESI I–II—cTnI 13.7 (10.3 to 17.9)
86.3 (82.1 to 89.7)
9.1 (3.5 to 21.8)
1.1 (0.3 to 3.3)
PESI I–II—TTE-RVD 12.3 (9.0 to 16.5)
87.7 (83.5 to 91.0)
10.8 (4.1 to 25.5)
1.1 (0.4 to 3.5)
PESI III–IV—BNP 56.3 (48.8 to 63.4)
43.8 (36.6 to 51.2)
10.1 (5.5 to 17.8)
6.5 (2.7 to 14.7)
PESI III–IV—cTnI 24.0 (18.2 to 30.9)
76.0 (69.1 to 81.8)
16.7 (8.2 to 31.0)
5.3 (2.5 to 10.6)
PESI III–IV—TTE-RVD 22.8 (17.0 to 29.9)
77.2 (70.1 to 83.0)
10.8 (4.1 to 25.5)
8.8 (4.9 to 15.2)
PESI V—BNP 76.2 (54.0 to 89.7)
23.8 (10.3 to 46.0)
18.8 (6.2 to 44.7)
8.3 (0.5 to 62.2)
PESI V—cTnI 30.0 (14.1 to 52.7)
70.0 (47.3 to 85.9)
16.7 (2.3 to 63.1)
14.3 (3.6 to 42.7)
PESI V—TTE-RVD 23.8 (10.3 to 46.0)
76.2 (54.0 to 89.7)
20.0 (2.7 to 69.1)
12.5 (3.1 to 38.6)
PESI+biomarkers
( Jimenez et al 2011)86 Update 1 Unclear
Prospective
Stable PE-related death 30 days
cTnI 32.1 (28.5 to 36.0)
67.9 (64.0 to 71.5)
10.5 (6.9 to 15.8)
4.2 (2.7 to 6.7)
TTE-RVD 20.3 (17.3 to 23.7)
79.7 (76.3 to 82.7)
11.7 (7.0 to 18.7)
4.9 (3.3 to 7.2)
US-DVT 38.6 (34.7 to 42.6)
61.4 (57.4 to 65.3)
9.6 (6.4 to 14.2)
4.1 (2.5 to 6.7)
TTE-RVD—cTnI 10.0 (7.8 to 12.7)
90.0 (87.3 to 92.2)
15.3 (8.1 to 26.8)
5.3 (3.7 to 7.5)
PESIIV—TTE-RVD—
cTnI
12.7 (9.0 to 17.7)
87.3 (82.3 to 91.0)
20.7 (9.6 to 39.0)
8.0 (5.0 to 12.7)
cTnI—US-DVT 13.9 (11.3 to 16.9)
86.1 (83.1 to 88.7)
17.1 (10.4 to 26.8)
4.5 (3.0 to 6.7)
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Table 4 Continued
Risk cut-off
(author, year)
Development
phase
N
studies Type of study
Haemodynamic
status Outcome
Time
point
Proportion
(95% CI)
High-risk group
Low-risk group
Event rate
(95% CI)
High-risk group
Low-risk group
PESIIV—cTnI—
US-DVT
18.0 (13.5 to 23.5)
82.0 (76.5 to 86.5)
24.4 (13.7 to 39.7)
6.4 (3.7 to 11.0)
TTE-RVD—US-DVT 8.6 (6.6 to 11.2)
91.4 (88.8 to 93.4)
19.6 (10.9 to 32.7)
5.0 (3.5 to 7.2)
TTE-RVD—cTnI—
US-DVT
4.1 (2.7 to 6.0)
95.9 (94.0 to 97.3)
20.8 (8.9 to 41.3)
5.6 (4.0 to 7.9)
PESIIV—TTE-RVD—
US-DVT
10.5 (7.2 to 15.2)
89.5 (84.8 to 92.8)
25.0 (11.7 to 45.6)
7.8 (4.9 to 12.4)
PREP—ClinII
(Sanchez et al 2010)110 Derivation 1 Prospective Stable Death VTE 30 days 32.3 (28.2 to 36.6)
67.7 (63.4 to 71.8)
12.3 (8 to 18.5)
2.5 (1.2 to 4.9)
PREP—ClinIII
(Sanchez et al 2010)110 Derivation 1 Prospective Stable Death VTE 30 days 1.9 (1 to 3.6)
98.1 (96.4 to 99)
22.2 (5.6 to 57.9)
4.9 (3.3 to 7.3)
sPESI1
(Dellas et al 2014)80 External validation 1 Prospective Stable Adverse outcome 30 days 66.1 (60.2 to 71.4)
33.9 (28.6 to 39.8)
11.2 (7.3 to 16.7)
0.5 (0 to 8)
(Lankeit et al 2011)94 External validation 1 Prospective Stable Death adverse
outcome
30 days 62.4 (58.1 to 66.4)
37.6 (33.6 to 41.9)
8.8 (6.2 to 12.4)
1 (0.3 to 3.9)
sPESI1-hscTnT
(Lankeit et al 2011)94 External validation 1 Prospective Stable Death adverse
outcome
30 days
hscTnT 59.3 (55.1 to 63.4)
40.7 (36.6 to 44.9)
8.7 (6.0 to 12.3)
1.9 (0.7 to 4.9)
sPESI1-hscTnT 75.9 (72.0 to 79.3)
24.1 (20.7 to 28.0)
7.8 (5.5 to 10.8)
0.4 (0.0 to 5.9)
In the first column, the cut-off is indicated by the corresponding higher risk group for the cut-off except for the Bova et al135 and Sanchez et al111 (PESI+biomarkers) studies which are displayed
in risk categories. Bova’s study combined IPD from six studies.
BNP, brain natriuretic peptide; cTnI, cardiac troponin I; cTnT, cardiac troponin T; DVT, deep vein thrombosis; GPS, Geneva prognostic score; hscTnT, high-sensitive cardiac troponin T; IPD,
individual patient data; NT-proBNP, N-terminal proBNP; PE, pulmonary embolism; PESI, Pulmonary Embolism Severity Index; PREP, Facteurs PRonostiques dans l’Embolie Pulmonaire; sPESI,
simplified PESI; TTE-RVD, transthoracic echocardiography-right ventricular dysfunction; US-DVT, ultrasound-detected DVT; VTE, venous thromboembolism.
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Table 5 Studies reporting on derivation and external validation of models originally not specific to the prognosis or the domain of PE (type 2 model studies), and studies
reporting on hospital criteria checklists (type 3 model studies)
Risk cut-off (author, year)
Development
phase
N
studies Type of study
Haemodynamic
status Outcome
Time
point
Proportion
(95% CI)
High-risk group
Low-risk group
Event rate
(95% CI)
High-risk group
Low-risk group
RGS
(Bertoletti et al 2013)73 External validation 1 Prospective for
RGS
Not reported All-cause death 3 months
RGS high 11.8 (8.8 to 15.5)
88.2 (84.5 to 91.2)
14.3 (6.6 to 28.3)
4.8 (2.9 to 7.7)
RGS high–intermediate 84.0 (79.9 to 87.5)
16.0 (12.5 to 20.1)
7.0 (4.6 to 10.5)
0.9 (0.1 to 12.3)
SGS
(Bertoletti et al 2013)73 External validation 1 Retrospective
for SGS
Not reported All-cause death 3 months
SGS high 7.8 (5.5 to 11.1)
92.2 (88.9 to 94.5)
17.9 (7.6 to 36.4)
4.9 (3.0 to 7.8)
SGS high–intermediate 84.0 (79.9 to 87.5)
16.0 (12.5 to 20.1)
7.0 (4.6 to 10.5)
0.9 (0.1 to 12.3)
GRACE—ACS risk score
(Paiva et al 2013)103 External validation 1 Retrospective Both stable and
unstable
All-cause death 30 days
GRACE—ACS high 56.8 (49.9 to 63.4)
43.2 (36.6 to 50.1)
25.6 (18.5 to 34.3)
10.1 (5.3 to 18.3)
GRACE—ACS high–
intermediate
81.1 (75.1 to 85.9)
18.9 (14.1 to 24.9)
23.4 (17.6 to 30.4)
1.3 (0.1 to 17.1)
GRACE—PE risk score
(Paiva et al 2013)103 External validation 1 Retrospective Both stable and
unstable
All-cause death 30 days
GRACE—PE high 49.0 (42.3 to 55.8)
51.0 (44.2 to 57.7)
29.7 (21.6 to 39.3)
8.6 (4.5 to 15.7)
GRACE—PE high–
intermediate
78.2 (72.0 to 83.3)
21.8 (16.7 to 28.0)
24.2 (18.2 to 31.4)
1.1 (0.1 to 15.1)
Davies checklist
(Davies et al 2007)79 Derivation 1 Prospective Not reported All-cause death 3 months
Unsuitable vs suitable 57.9 (51.0 to 64.5)
42.1 (35.5 to 49.0)
5.1 (2.3 to 10.9)
3.5 (1.1 to 10.4)
Continued
18
Elias
A,etal.BM
J
Open
2016;6:e010324.doi:10.1136/bm
jopen-2015-010324
O
p
e
n
A
c
c
e
s
s
 on 31 May 2018 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2015-010324 on 29 April 2016. Downloaded from 
Table 5 Continued
Risk cut-off (author, year)
Development
phase
N
studies Type of study
Haemodynamic
status Outcome
Time
point
Proportion
(95% CI)
High-risk group
Low-risk group
Event rate
(95% CI)
High-risk group
Low-risk group
Davies checklist
(Davies et al 2007)79 External validation
and impact
(management
study)
1 Prospective Stable meeting
inclusion criteria
(suitable) for
home treatment
All-cause death 3 months Not reported 1.9 (0.4 to 5.5)
PE-related None
VTE None
Major/fatal bleeding None
Hestia checklist
(Zondag et al 2013)125 External validation 1 Prospective Both stable and
unstable
All-cause death 30 days 46.9 (42.4 to 51.4)
53.1 (48.6 to 57.6)
4.1 (2.2 to 7.7)
0.8 (0.2 to 3.2)
3 months 46.9 (42.4 to 51.4)
53.1 (48.6 to 57.6)
9.6 (6.4 to 14.3)
1.2 (0.4 to 3.7)
7 days 46.9 (42.4 to 51.4)
53.1 (48.6 to 57.6)
1.8 (0.7 to 4.8)
0.2 (0.0 to 3.1)
Hestia checklist
(Zondag et al 2013)126 External validation
(and update)
1 Prospective Both stable and
unstable
All-cause death 30 days 44.6 (40.2 to 49.0)
55.4 (51.0 to 59.8)
4.1 (2.1 to 7.6)
0.7 (0.2 to 2.9)
Both stable and
unstable
Death adverse
outcome
30 days 44.6 (40.2 to 49.0)
55.4 (51.0 to 59.8)
19.9 (15.2 to 25.7)
0.7 (0.2 to 2.9)
Stable All-cause death 30 days 41.5 (37.1 to 46.0)
58.5 (54.0 to 62.9)
3.6 (1.7 to 7.3)
0.7 (0.2 to 2.9)
Stable Death adverse
outcome
30 days 41.5 (37.1 to 46.0)
58.5 (54.0 to 62.9)
10.3 (6.7 to 15.4)
0.7 (0.2 to 2.9)
ACS, acute coronary syndrome; GRACE, Global Registry of Acute Coronary Events; PE, pulmonary embolism; RGS, revised Geneva score; SGS, simplified Geneva score; VTE, venous
thromboembolism.
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Model updating
For better identiﬁcation of lower and higher risk groups,
some studies assessed the effect on outcomes of adding
one or more prognostic variables to an existing model.
There is increasing evidence about the greater effective-
ness of these ‘new models’, even though the existing
ones such as PESI, sPESI and PREP are already highly
effective.
In the study of Moores, the addition of non-elevated
cTnI to low-risk PESI did not improve the negative pre-
dictive value compared with either test alone.96 In the
Lankeit study,94 the combination of a negative high-
sensitive cTnT (hscTnT<14 pg/mL) and a sPESI value
of 0 at baseline improved risk classiﬁcation and reduced
the risk of mortality. The same applies for the combin-
ation of NT-proBNP (<600 pg/mL) and low-risk sPESI.95
In the study of Ozsu, hscTnT combined with sPESI pro-
vided better predictive information than cTnT.101
Adding cTn to the PESI113 and the sPESI115 models
resulted in a higher area under the curve (AUC) value
with no additive value for Ddimer to PESI and cTn.113
To sum up, there is an increased value in identifying
lower risk patients by adding NT-proBNP and hscTnT to
PESI or sPESI.
Figure 2 sROC plots showing test accuracy of PESIIII cut-off associated with 30-day all-cause death: all studies (A) and
external validation studies (B). HSROC, hierarchical summary receiver operating characteristic; PESI, Pulmonary Embolism
Severity Index; sROC, summary receiver operating characteristic.
Figure 3 sROC plots showing test accuracy of sPESI1 cut-off associated with 30-day all-cause death: all studies (A) and
external validation studies (B). HSROC, hierarchical summary receiver operating characteristic; PESI, Pulmonary Embolism
Severity Index; sROC, summary receiver operating characteristic.
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Other update studies tried to improve the identiﬁca-
tion of high-risk patients. Adding BNP and TTE-RVD
to the PREP clinical model resulted in a signiﬁcant dif-
ference in AUC.110 A signiﬁcant increase in ‘NRI: Net
Reclassiﬁcation Improvement’, as deﬁned by Pencina et
al,142 was obtained in the original study which updated
PREP model by adding BNP and TTE-RVD to the clin-
ical model.110 Using the PREP cohort in patients with
normotensive PE, Sanchez et al showed that biomarkers
(cTnI, BNP) and echocardiography provided additional
prognostic information to PESI.111 In the Palmieri
study104 which included highly selected ‘non-massive
central PE’, increased cTnI contributed to identifying
patients with increased risk of development of haemo-
dynamic instability, which was independent of, and in
addition, to PESI. Novel models80 87 92 135 speciﬁcally
developed for patients with normotensive PE and
integrating biomarkers (cTn, NT-proBNP, heart-type
fatty acid-binding protein (H-FABP)), CT or TTE-RVD
and US-detected DVT with clinical variables (SBP, HR)
or with sPESI, showed a high ability to identify
patients at lower risk as well as at higher risk of early
death or adverse outcome at the expense of a
lower proportion of patients in these risk groups
(tables 3 and 4).
Tests of heterogeneity, investigation for publication bias,
subgroup analysis and sensitivity analysis
Results of tests for heterogeneity using Cochran’s Q test
and Higghins I2 statistic, and results of subgroup ana-
lyses show major problems of heterogeneity. Comparing
results between studies reporting on 30-day all-cause
death for PESI optimal cut-offs (PESIIII, sPESI1), all
conditions for comparison being optimal (all studies are
retrospective and external validation studies, and
include ‘both stable and unstable’ patients with PE), we
found important between-study heterogeneity (for
instance for PESI: Q value=39.69, df 5, p=0.000, I2=87)
that might be related to only patient selection in studies.
A high proportion of patients at low risk in study popula-
tion (or a lower proportion of patients at high risk)
results in less event rates in the population sample and
less event rates within risk groups as shown on forest
plots (see online supplementary ﬁgures S7–S12).
Heterogeneity (I2>50%) was observed in most of the
analyses for 30-day all-cause death with PESIIII and
sPESI. At best I2 test for heterogeneity was 39% (all
studies combined) and 50% (external validation studies
only) in low-risk PESI group.
Findings from the investigation for publication bias
using the ‘Funnel Plot’ of SE and precision (=1/SE) by
Logit event rate (with comparison of plots with observed
studies against plots with observed and imputed
studies), and the Egger’s test of regression intercept
show no evidence of publication bias except for studies
using PESIIII and PESI=V cut-offs for 30-day all-cause
death (see online supplementary ﬁgures S13.1 and
S13.2).
Model impact
The clinical utility of a model is assessed by its effect on
clinical decision-making and subsequent patient out-
comes. However, few such studies have been performed
of the PE models (see online supplementary table S2.4).
The safety of treating patients with low-risk PE as out-
patients was examined in two management studies66 128
and in two randomised trials.71 100 The ﬁrst management
study128 was a feasibility study among low-risk patients
based on the GPS model in a very small number of
patients. It showed the use of the GPS model to be safe.
In the other one-arm management study, patients with
stable PE with NT-proBNP<500 pg/mL were treated at
home. Seven (4.6%) patients were readmitted within the
ﬁrst 10 days, but there were no deaths, no VTE events
and no clinically relevant or major bleeding at 3-month
follow-up. The ﬁrst of the two randomised trials100 did
not demonstrate the clinical utility of Uresandi’s
model118 for outpatient management. The rate of short-
term mortality was unexpectedly high in both manage-
ment groups, as was the rate of VTE events and major
bleeding. The second randomised trial71 was a non-
inferiority study in highly selected patients with low-risk
PE. It showed that outpatient care based on the PESI
model can safely and effectively be used in place of
inpatient care: 1 (0.6%) death in each group, with 1
(0.6%) VTE and 2 (1.2%) major bleeding events in the
outpatient group at a 3-month follow-up. Owing to other
eligibility criteria for outpatient management and study
design, only 56% (152/271) with low NT-proBNP level,66
13% (132/1016) with low-risk Uresandi’s model,100 18%
(43/244) with low-risk GPS128 and 44% (344/783) with
PESI I-II71 could be treated as outpatients.
The PEITHO study132 randomised patients with
normotensive PE at ‘intermediate–high’ risk (with RVD
and myocardial injury) to receive tenecteplase (ﬁbrino-
lytics) or placebo. Death or hemodynamic decompensa-
tion occurred in 13/506 patients (2.6%) in the
tenecteplase group as compared with 28/499 (5.6%) in
the placebo group. Fibrinolytic therapy did not prevent
in-hospital death and increased the risk of major haem-
orrhage and stroke. Models are less speciﬁc for predict-
ing poor outcome in normotensive high-risk patients
and might beneﬁt from combining prognostic variables
for better selection of patients, in particular those at risk
of death from PE, as long as patients who are likely to
respond to therapy are identiﬁed.
Finally, risk stratiﬁcation was found to be frequently
performed in patients admitted with acute PE and found
to be stable during a 5-year period.133 Its use was asso-
ciated with assignment to higher levels of care and more
intense treatment, but did not improve the outcome.133
DISCUSSION
Summary of main results
This systematic review identiﬁed 17 prognostic models in
acute PE and other types of models that were not
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originally speciﬁc to PE or exclusively to its prognosis.
Eight models were validated or updated and three were
assessed in impact studies. Overall, PESI and sPESI are
the models that have been most widely validated and
updated, and PESI is the only one that has been assessed
and found useful in a randomised trial for treating
patients with low-risk PE as outpatients (level 1 of hier-
archy of evidence according to McGinn et al143). As
expected, the event rates for different outcomes and
time points increase along the risk scale in PESI model.
The attempt to simplify PESI is attractive and successful
in validation studies, but needs to be evaluated in
impact studies. Agreement between the simpliﬁed PESI
and the original PESI is fair.106 PESI and sPESI models
are now included in the risk stratiﬁcation of patients
with PE in the 2014 ESC guidelines.3 This new strategy
needs to be validated and compared to the existing
models. Other prognostic models have shown improve-
ment in identifying low-risk and high-risk groups either
on their own (algorithm for the low risk—Shock Index,
2008 ESC high, PREP—Clin III, PESIIV, PESI V,
eStiMaTe high, FAST 3, Bova stage III for the high risk),
or by the addition of one or more clinical, biological
and imaging-based markers of RVD and myocardial
injury to the existing models or by incorporating these
markers into new models (NT-proBNP and hscTn for
the low risk—SBP, BNP, cTN, H-FABP, venous US and
imaging-based RVD for the high risk). Large validation
and impact studies are needed to assess these new and
updated models.
Overall completeness and applicability of evidence
Most of the models are effective and provide a low event
rate in low-risk groups, and appear reproducible and
robust. However, using the model for identifying the
low-risk groups may not be worthwhile if the aim is to
make a choice to send the patients home; because the
patients might still have an unacceptable high risk of a
serious adverse outcome. It is important to deﬁne the
incidence limit for a speciﬁc outcome, which should be
clinically relevant and if models go beyond this they
should not be viewed as of high performance. In agree-
ment with the review of Vinson et al,144 careful selection
is needed for low-risk patients with acute PE who will be
managed as outpatients. Broad implementation of this
management strategy is controversial and varies across
countries and across organisation of patient care and
patient pathways. Furthermore, decisions about manage-
ment might be modiﬁed by the availability of new oral
anticoagulants being studied in large-scale clinical
trials.144 Hospital checklist criteria79 125 should also be
helpful for patient selection and seem to be competitive
with prognostic models.
Differences in predictive performance of the models
may be due to differences in prognostic criteria and
threshold for risk groups regardless of study design,
development phase, population, outcome and time
point. In two model construction studies68 69 using the
same cohort and the same outcome, a change in criteria
and threshold resulted in change of risk group propor-
tions and event rates within these risk groups. Shifting
the cut-off to reduce the incidence of events in the
low-risk group led to a smaller proportion of patients in
the low-risk group, and selecting patients with lower risk
PE makes the model more effective but less efﬁcient.
This also applies to the high-risk patient groups: the
greater the proportion of patients classiﬁed as high risk,
the lower the incidence of outcomes in this group and
vice versa. Adding biomarker data may help to identify
higher or lower risk patients, but the ﬁndings on the
additive value of biomarkers are inconsistent across
studies. This may be explained by the higher predictive
performance of some models, heterogeneity in the
populations arising from study design66 71 100 or a
higher sensitivity of some biomarkers.94
Quality of the evidence
In our review, we used a comprehensive search strategy,
assessed the quality of the included studies to allow us
to focus on those of good quality, and used statistical
techniques to analyse their results and combine and
compare the ﬁndings. However, the included studies
contain some methodological ﬂaws in the design,
conduct and reporting. Many are retrospective or use
prospectively collected data for diagnosis purposes, and
one of the most common limitations is the lack of
reporting of the case-ascertainment strategy used in the
study. These problems might lead to selection bias that
could have affected the event rates and inﬂuence the
variables included in the ﬁnal model. The time of
inception of the cohorts (ie, whether it was at diagnosis
or on admission) was ill deﬁned and patient selection
may have been different across studies. Other common
methodological issues are the lack of a justiﬁcation for
the sample size, the absence of a full deﬁnition of prog-
nostic variables and the lack of standardisation of treat-
ments which might have been dictated by the
prognostic variables that were assessed (and, therefore,
may have affected the likelihood of certain outcomes),
the lack of blinded assessment of the outcomes (to the
prognostic variables), and possible problems with data
analysis related to the statistical methods for missing
data.
Potential biases in the review process
Our search was performed up to July 2014. Publications
after that date were not included in the review. We
believe there are no biases in our searches within the
search period and decisions on study eligibility.
Although we used a highly sensitive search to minimise
the inﬂuence of reporting biases related to duplicate
and cumulative full publication, time lag, language, loca-
tion and reference list citation,17 it is not possible to
know how a study’s ﬁndings might inﬂuence the
researchers’ decision to publish it; unlike in randomised
trials where positive results for new treatments are more
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Table 6 Comparison of our study with existing systematic reviews and meta-analyses of clinical prediction rules
Author, year
Squizatto et al,
2012146 Zhou et al, 2012148 Kohn et al, 2015147 Our study
Study design Systematic review and
meta-analysis
Meta-analysis Systematic review and
meta-analysis
Systematic review and meta-analysis
Years of search Until August 2011 Up to June 2012 January 2000–March 2014 Inception to July 2014
Databases for search MEDLINE, EMBASE MEDLINE, EMBASE MEDLINE, EMBASE MEDLINE, EMBASE, The Cochrane Library
Language included No language restriction English English No language restriction
Number of studies in review 33 21 40 71
Type of studies included Derivation, validation Validation (external) Derivation, validation Derivation, validation, update and impact
Number of models in review 9 2 11 17 (+7 other types of models*)
Type of models included Clinical prediction rules PESI and sPESI Clinical prediction rules All prognostic models
Quality appraisal method used 3-point score for cohort
studies
Newcastle-Ottawa Scale QUADAS2 (diagnostic tool)
Domain approach
Prognostic criteria
Domain approach
Analysis of stable PE patients
separately
No No No Yes
Outcome All-cause mortality,
adverse outcomes
All-cause mortality, PE-related
mortality, adverse outcomes
All-cause mortality All-cause mortality, PE-related mortality,
adverse outcomes, VTE, major bleeding
Analysis of different outcomes
separately
Yes Yes Not applicable Yes
Time point 14 days, 30 days,
3 months
Not reported In-hospital, 7 days, 30 days,
3 months
In-hospital/7 days, 30 days, 3 months
Analysis of different time
points separately
No No No Yes
Risk groups Low-risk group Low-risk group vs high-risk
group
Low-risk group Low-risk group and high-risk group
Number of cut-offs accounted
for
Single cut-off Single cut-off Single cut-off All available cut-offs (analysis along the risk
scale)
Summary estimate in
meta-analysis
Event rate in patients at
low risk for all models
combined
Prognostic accuracy,† OR Prognostic accuracy† Prognostic accuracy,† proportion of patients in
each risk group, event rates within each risk
group (absolute risk), population event rate
Overall summary estimate
from combined derivation and
validation studies
Yes No Yes Yes
Summary estimate from
external validation studies
No Yes No Yes
Analysis of update studies No No No Yes
Analysis of impact studies No No No Yes
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likely to lead to full publication. To assess publication
bias for proportion and event rates, we applied statistical
tests to detect funnel plot asymmetry, but we found little
evidence of publication bias. According to Macaskill
et al,145 ‘applying such tests in systematic review of diag-
nostic test accuracy is likely to result in publication bias
being incorrectly indicated by the test far too often’.
Data extraction was performed by two reviewers. The
second reviewer was not blinded to the data extracted.
To ensure quality, data were rechecked by the ﬁrst
reviewer. We assessed study quality using a domain
approach17 rather than a scale. This is more transparent
to the reader, by showing how each study is performed
in each aspect of conduct. As shown by Juni et al,19 ‘the
use of summary scores to identify trials of high quality is
problematic and relevant methodological aspects should
be assessed individually and their inﬂuence on effect
sizes explored’.
Our analyses were performed for distinct models, out-
comes/time points, with subgroup and sensitivity ana-
lyses to deal with heterogeneity. We used multiple
statistical techniques, which could introduce bias in the
selection of results to present, but no discrepancies were
found across the results and all analyses are available.
We used absolute risk rather than relative risk because
this is more appropriate for estimating the risks for indi-
vidual patients.
Comparison with other reviews
This study was not limited to only clinical prediction
rules and to our knowledge, it is the ﬁrst broad system-
atic review and meta-analysis of prognostic models in
patients with acute PE. There are two published system-
atic reviews on clinical prediction rules146 147 and a
meta-analysis of PESI models,148 but, as discussed below,
our systematic review has important differences to all of
these, expands their scope considerably and provides
more comprehensive and up-to-date data (table 6).
We believe the key strengths of our review are well-
deﬁned selection criteria, broad search strategy, and
presentation of results of all available predictive models
with full details on study characteristics, population and
prognostic information and study quality. We used a
domain approach and prognostic criteria for the assess-
ment of study quality. Quantitative analyses are provided
to answer each aspect of model development in accord-
ance with the recommendations of recently published
guidelines for prognostic model research,149 for differ-
ent outcomes and time points in ‘both stable and
unstable’ as well as in ‘stable’ PE, and at various
cut-offs, with the aim of improving management of
patients with acute PE who are either at low risk or at
high risk. For the analysis of performance, we provide a
summary estimate of sensitivity and speciﬁcity and also
a summary estimate of event rates (‘absolute risk’149)
within risk groups, which is more meaningful for clini-
cians and seems more appropriate for the study of
prognosis.
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CONCLUSIONS
Our systematic review provides useful information on
the prediction ability and the utility of existing prognos-
tic models in acute PE that might help clinicians and
researchers for the identiﬁcation of patients at low risk
of events for safe early discharge or outpatient manage-
ment and those at high risk who may need closer moni-
toring or more aggressive therapy. It shows the potential
for improving the selection of lower risk and higher risk
groups in patients with normotensive PE with novel and
updated models that integrate biomarkers (cTn, BNP,
NT-proBNP, H-FABP), CT or TTE-RVD and US-detected
DVT into existing models or with other clinical variables
(systolic blood pressure, heart rate). These ﬁndings
provide a good direction for future research in valid-
ation and impact studies.
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